The European Medicines Agency is this week deciding whether to recommend pan-EU marketing authorization for several new medicines, including ponesimod, Janssen Pharmaceutical’s treatment for relapsing forms of multiple sclerosis (MS) that has just been approved in the US.
Ponesimod, approved by the US Food and Drug Administration under the brand name Ponvory, is a once-daily oral selective sphingosine-1-phosphate...








